About Systemic Psoriasis Therapeutics
Psoriasis is a chronic skin disease affecting about 2% of the world’s population. Different forms of psoriasis include plaque, inverse, pustular, and guttate psoriasis.
Technavio’s analysts forecast the Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the systemic psoriasis therapeutics market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, systemic psoriasis therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Amgen
• Celgene
• Johnson & Johnson
Market driver
• Need for affordable therapies
• For a full, detailed list, view our report
Market challenge
• Patent expiry of drugs
• For a full, detailed list, view our report
Market trend
• Rise in cost of systemic psoriasis therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE ANALYSIS
• Pipeline analysis
• Discontinued psoriasis therapies
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2017-2022
• Biologics – Market size and forecast 2017-2022
• Market opportunity by product
PART 09: MARKET SEGMENTATION BY ROA
• Segmentation by ROA
• Oral
• Parenteral
PART 10: MARKET SEGMENTATION BY SEVERITY OF DISEASE
• Segmentation by severity of disease
PART 11: MARKET SEGMENTATION BY END-USER
• Segmentation by end-user
• Hospitals
• Retail pharmacies
PART 12: CUSTOMER LANDSCAPE
PART 13: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 14: DECISION FRAMEWORK
PART 15: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 16: MARKET TRENDS
• Rise in cost of systemic psoriasis therapy
• Introduction of biologics
• Gene therapy for psoriasis
• Use of combination therapy
• Research in precision healthcare infrastructure
PART 17: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 18: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Celgene
• Johnson & Johnson
PART 19: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global systemic psoriasis therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global systemic psoriasis therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Relationship between need, supply, and demand
Exhibit 18: List of biosimilars approved by FDA for psoriasis
Exhibit 19: List of biosimilars approved by European Medicines Agency (EMA) for psoriasis
Exhibit 20: List of biologics and small molecules (phase II and III in pipeline) and MOA
Exhibit 21: List of biosimilars (phase II and III in pipeline) and MOA
Exhibit 22: Biologics targeting IL-23 and IL-17
Exhibit 23: Global systemic psoriasis therapeutics market by product – Market share 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global systemic psoriasis therapeutics market by small molecules – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global systemic psoriasis therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global systemic psoriasis therapeutics market by biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global systemic psoriasis therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Global systemic psoriasis therapeutics market by region – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global systemic psoriasis therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Global systemic psoriasis therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in Americas
Exhibit 36: Global systemic psoriasis therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: Global systemic psoriasis therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in EMEA
Exhibit 39: Global systemic psoriasis therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: Global systemic psoriasis therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top three countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AbbVie overview
Exhibit 49: AbbVie – Business segments
Exhibit 50: AbbVie – Organizational developments
Exhibit 51: AbbVie – Geographic focus
Exhibit 52: AbbVie – Segment focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: Amgen overview
Exhibit 55: Amgen – Business Segments
Exhibit 56: Amgen – Organizational developments
Exhibit 57: Amgen – Geographic focus
Exhibit 58: Amgen – Segment focus
Exhibit 59: Amgen – Key offerings
Exhibit 60: Celgene overview
Exhibit 61: Celgene – Business segments
Exhibit 62: Celgene – Organizational developments
Exhibit 63: Celgene – Geographic focus
Exhibit 64: Celgene – Segment focus
Exhibit 65: Celgene – Key offerings
Exhibit 66: Johnson & Johnson overview
Exhibit 67: Johnson & Johnson – Business segments
Exhibit 68: Johnson & Johnson – Organizational developments
Exhibit 69: Johnson & Johnson – Geographic focus
Exhibit 70: Johnson & Johnson – Segment focus
Exhibit 71: Johnson & Johnson – Key offerings
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE ANALYSIS
• Pipeline analysis
• Discontinued psoriasis therapies
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2017-2022
• Biologics – Market size and forecast 2017-2022
• Market opportunity by product
PART 09: MARKET SEGMENTATION BY ROA
• Segmentation by ROA
• Oral
• Parenteral
PART 10: MARKET SEGMENTATION BY SEVERITY OF DISEASE
• Segmentation by severity of disease
PART 11: MARKET SEGMENTATION BY END-USER
• Segmentation by end-user
• Hospitals
• Retail pharmacies
PART 12: CUSTOMER LANDSCAPE
PART 13: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 14: DECISION FRAMEWORK
PART 15: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 16: MARKET TRENDS
• Rise in cost of systemic psoriasis therapy
• Introduction of biologics
• Gene therapy for psoriasis
• Use of combination therapy
• Research in precision healthcare infrastructure
PART 17: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 18: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Celgene
• Johnson & Johnson
PART 19: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global systemic psoriasis therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global systemic psoriasis therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Relationship between need, supply, and demand
Exhibit 18: List of biosimilars approved by FDA for psoriasis
Exhibit 19: List of biosimilars approved by European Medicines Agency (EMA) for psoriasis
Exhibit 20: List of biologics and small molecules (phase II and III in pipeline) and MOA
Exhibit 21: List of biosimilars (phase II and III in pipeline) and MOA
Exhibit 22: Biologics targeting IL-23 and IL-17
Exhibit 23: Global systemic psoriasis therapeutics market by product – Market share 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global systemic psoriasis therapeutics market by small molecules – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global systemic psoriasis therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global systemic psoriasis therapeutics market by biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global systemic psoriasis therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Global systemic psoriasis therapeutics market by region – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global systemic psoriasis therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Global systemic psoriasis therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in Americas
Exhibit 36: Global systemic psoriasis therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: Global systemic psoriasis therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in EMEA
Exhibit 39: Global systemic psoriasis therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: Global systemic psoriasis therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top three countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AbbVie overview
Exhibit 49: AbbVie – Business segments
Exhibit 50: AbbVie – Organizational developments
Exhibit 51: AbbVie – Geographic focus
Exhibit 52: AbbVie – Segment focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: Amgen overview
Exhibit 55: Amgen – Business Segments
Exhibit 56: Amgen – Organizational developments
Exhibit 57: Amgen – Geographic focus
Exhibit 58: Amgen – Segment focus
Exhibit 59: Amgen – Key offerings
Exhibit 60: Celgene overview
Exhibit 61: Celgene – Business segments
Exhibit 62: Celgene – Organizational developments
Exhibit 63: Celgene – Geographic focus
Exhibit 64: Celgene – Segment focus
Exhibit 65: Celgene – Key offerings
Exhibit 66: Johnson & Johnson overview
Exhibit 67: Johnson & Johnson – Business segments
Exhibit 68: Johnson & Johnson – Organizational developments
Exhibit 69: Johnson & Johnson – Geographic focus
Exhibit 70: Johnson & Johnson – Segment focus
Exhibit 71: Johnson & Johnson – Key offerings
